- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03132155
QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma
A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma That Contains the Ewing Sarcoma Breakpoint Region 1-activating Transcription Factor-1 (EWSR1-ATF1) Gene Fusion
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
El Segundo, California, United States, 90245
- Chan Soon-Shiong Institute for Medicine
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas, MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to understand and provide a signed informed consent that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.
- Able to attend required study visits and return for adequate follow-up, as required by this protocol.
- Able to self-administer AMG 337 as a whole capsule by mouth every day.
- Age ≥ 16 years.
- Histologically confirmed, unresectable, locally advanced or metastatic tumors that contain the EWSR1-ATF1 gene fusion, as determined by fluorescent in situ hybridization (FISH) or other diagnostic methods and confirmed by RNA sequencing (RNAseq).
- Have measurable disease evaluable in accordance with RECIST Version 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Must have a recent Formalin-fixed paraffin-embedded (FFPE) tumor biopsy specimen that was obtained following the conclusion of the most recent anticancer treatment. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period.
- Must be willing to undergo a biopsy during the treatment period, if considered safe by the investigator.
- Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
Hematologic function, as follows:
- Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.
- Platelet count ≥ 50 × 109/L.
- Hemoglobin > 8 g/dL.
- Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.5 × upper limit of normal (ULN), except for subjects on anticoagulation therapy for venous thromboembolism.
Renal function, as follows:
a. Calculated creatinine clearance > 30 mL/min.
Hepatic function, as follows:
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 × ULN and total bilirubin < 1.5 × ULN.
- Alkaline phosphatase (ALP) < 2 × ULN (≤ 5 × ULN if bone or liver metastases are present)
- Agreement to practice effective contraception (both male and female subjects, if the risk of conception exists).
Exclusion Criteria:
- Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
- Inability to attend required study visits and return for adequate follow-up, as required for this protocol.
- Known hypersensitivity to any component of the study medication(s).
- Women who are nursing, pregnant, or planning to become pregnant during the duration of the study.
Current diagnosis or history of a second neoplasm, except the following:
a. Adequately treated non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated with no evidence of disease for ≥ 2 years.
- History of bleeding diathesis.
- Uncontrolled hypertension (systolic > 160 mmHg and/or diastolic > 100 mmHg) or clinically significant cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months before study day 1; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication.
- Baseline ECG Fridericia's formula QTcF > 470 ms.
- Active infection requiring intravenous (IV) antibiotics within 2 weeks before study day 1.
- Significant gastrointestinal disorder (eg, Crohn's disease, ulcerative colitis, extensive gastrointestinal resection) that in the opinion of the Investigator may influence drug absorption.
- Positive result of screening test for human immunodeficiency virus (HIV).
- Evidence of acute hepatitis B and C. Subjects with chronic hepatitis B or C are eligible if their condition is stable and, in the opinion of the investigator, would not pose a risk to subject safety.
Toxicities from prior anti-tumor therapy not resolved to CTCAE Version 4.03 grade 0 or 1.
a. Grade 2 toxicities from prior anti-tumor therapy that are considered irreversible (defined as having been present or stable for > 4 weeks), such as stable grade 2 peripheral neuropathy or ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria.
- Participation in this study or in an investigational study and/or procedure with any molecularly targeted agents reported to inhibit Mesenchymal epithelial transition factor (MET) within 14 days before study day 1.
- Anti-tumor therapy, including chemotherapy, antibody therapy, retinoid therapy, or other investigational therapy within 14 days before study day 1.
- Therapeutic or palliative radiation therapy within 14 days before study day 1.
- Major surgery within 28 days before study day 1.
- Any comorbidity that in the opinion of the investigator may increase the risk of toxicity.
- Concurrent or prior use of a strong CYP3A4 inhibitor within 14 days before study day 1, including the following: ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole.
- Concurrent or prior ingestion of grapefruit or grapefruit products, or other foods known to inhibit CYP3A4 within 7 days before study day 1.
- Concurrent or prior use of strong CYP3A4 inducers within 28 days before study day 1, including the following: phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, or the herbal supplement St. John's Wort.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AMG 337
AMG 337 will be administered in patients with advanced or metastatic clear cell sarcoma
|
6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: 1 year
|
Confirmed ORR (confirmed complete response or partial response) will be evaluated in accordance with RECIST Version 1.1 by BICR.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events (Safety And Tolerability)
Time Frame: 1 year
|
To evaluate the safety of AMG 337 based on grade 3 or 4 non-hematologic toxicity.
|
1 year
|
Progression-free Survival (PFS)
Time Frame: 1 year
|
To determine PFS, evaluated in accordance with RECIST Version 1.1 BICR.
|
1 year
|
Overall Survival (OS)
Time Frame: 1 year
|
To determine OS, defined as the time from the date of the first administration of therapy to the date of death.
|
1 year
|
Duration of Response (DOR)
Time Frame: 1 year
|
To determine DOR, measured by RECIST Version 1.1 by BICR.
|
1 year
|
Disease Control Rate (DCR)
Time Frame: 4 months
|
To determine DCR (confirmed CR, PR, or SD) lasting for at least 4 months by BICR.
|
4 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- QUILT-3.031
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clear Cell Sarcoma
-
Wuhan Union Hospital, ChinaRecruitingClear Cell Sarcoma of Soft TissueChina
-
National Cancer Institute (NCI)Active, not recruitingDedifferentiated Chondrosarcoma | Central Chondrosarcoma, Grade 2 | Central Chondrosarcoma, Grade 3 | Metastatic Clear Cell Sarcoma of Soft Tissue | Metastatic Primary Central Chondrosarcoma | Unresectable Primary Central ChondrosarcomaUnited States, Canada
-
ArQule, Inc. (a wholly owned subsidiary of Merck...CompletedRenal Cell Carcinoma (RCC) | Alveolar Soft Part Sarcoma (ASPS) | Clear Cell Sarcoma (CCS)United States, Canada, United Kingdom
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedBone Cancer | Chondrosarcoma | Recurrent Osteosarcoma | Clear Cell Sarcoma of the Kidney | Metastatic Osteosarcoma | Ovarian Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Uterine Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage III Uterine Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage...United States
-
Roswell Park Cancer InstitutePfizerCompletedRecurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Clear Cell Sarcoma of the KidneyUnited States, Netherlands
-
Institut Claudius RegaudRecruitingSoft Tissue Sarcoma | Perivascular Epithelioid Cell Neoplasms | Epithelioid Sarcoma | Alveolar Soft Part Sarcoma | Desmoplastic Small Round Cell Tumor | Clear Cell Sarcoma | Sclerosing Epithelioid Fibrosarcoma | Low Grade Fibromyxoid Sarcoma | Malignant Solitary Fibrous Tumors | Epithelioid HemangioendotheliomaFrance
-
Italian Sarcoma GroupGlaxoSmithKlineTerminated
-
Cornerstone PharmaceuticalsCompleted
-
Salarius Pharmaceuticals, LLCNational Pediatric Cancer FoundationActive, not recruitingEwing Sarcoma | Myxoid Liposarcoma | Fibromyxoid Tumor | Sarcoma,Soft Tissue | Desmoplastic Small Round Cell Tumor | Angiomatoid Fibrous Histiocytoma | Extraskeletal Myxoid Chondrosarcoma | Clear Cell Sarcoma | Primary Pulmonary Myxoid Sarcoma | Myoepithelial Tumor | Sclerosing Epithelioid FibrosarcomaUnited States
-
Salarius Pharmaceuticals, LLCEnrolling by invitationEwing Sarcoma | Myxoid Liposarcoma | Desmoplastic Small Round Cell Tumor | Angiomatoid Fibrous Histiocytoma | Extraskeletal Myxoid Chondrosarcoma | Clear Cell Sarcoma | Myoepithelial Tumor | Sclerosing Epithelioid Fibrosarcoma | Low Grade Fibromyxoid SarcomaUnited States
Clinical Trials on AMG 337
-
AmgenTerminatedStomach NeoplasmsBelgium, France, Italy, Spain, Czechia, Poland, United States, Korea, Republic of, Russian Federation, Canada, United Kingdom, Australia, Austria, Germany, Hungary, Greece, Peru, Chile
-
AmgenCompletedCancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology PatientsUnited States
-
NantPharma, LLCWithdrawn
-
SoseiCompletedFibromyalgiaUnited Kingdom
-
University of FloridaInventiva PharmaCompletedNonalcoholic Fatty Liver Disease (NAFLD) | Type 2 Diabetes (T2DM)United States
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI); ECOG-ACRIN Cancer Research GroupWithdrawnGastrointestinal Cancer | Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Adenocarcinoma of the Esophagus | Stage IV Esophageal Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric... and other conditionsUnited States
-
AmgenCompletedAdvanced Solid TumorsBelgium, Canada, Australia, United States, Spain, Poland, France, Germany, Japan, United Kingdom
-
AmgenTerminatedRelapsed/Refractory Acute Myeloid Leukemia (AML)United States, Korea, Republic of, Australia, Japan, Germany, Canada
-
AmgenTerminatedCutaneous Lupus | LupusUnited States, Australia, Canada